Source - LSE Regulatory
RNS Number : 3228D
Immupharma PLC
28 June 2021
 

 

 

 

28 June 2021

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

2021 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

 

ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed.

The results of each resolution were as follows:

 

Resolution

For

% For

Against

% Against

Withheld

1. To receive the accounts of the Company for the year ended 31 December 2020 together with the reports thereon of the directors and auditors of the Company

27,979,197

99.93

20,000

0.07

663,319

2. To re-appoint Dr Stephane Mery as a director of the Company

22,040,754

76.93

6,610,683

23.07

11,079

3. To re-appoint Nexia Smith & Williams as auditors of the Company

28,003,061

99.92

22,348

0.08

637,107

4. That the directors be authorised to allot shares on the basis set out in the Notice of Meeting

27,762,710

99.82

48,844

0.18

850,962

5. To waive pre-emption rights in respect of the issue of the shares on the basis set out in the Notice of Meeting

27,759,210

99.81

52,344

0.19

850,962

 

As at the date of the AGM, the number of issued ordinary shares of the Company was 250,221,2975 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

 

End

 

 

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

John Howes

Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

 

Degroof Petercam (Liquidity Provider)

Erik De Clippel

 

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60

 

 

+32 (0) 2 287 95 34

 

 

 

+32 (0) 477 504 784

+32 (0) 475 903 909

 

 

 

 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk 

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGDKFBKKBKDBAB
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.